A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Trial Profile

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2018

At a glance

  • Drugs G1T-48 (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors G1 Therapeutics
  • Most Recent Events

    • 09 May 2018 Status changed from not yet recruiting to recruiting.
    • 03 May 2018 According to a G1 Therapeutics media release, the company anticipates to initiate the trial in the second quarter of 2018.
    • 06 Mar 2018 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top